Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement
- PMID: 16144894
- DOI: 10.7326/0003-4819-143-5-200509060-00011
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement
Erratum in
- Ann Intern Med. 2005 Oct 4;143(7):547
Abstract
This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility, along with the supporting scientific evidence. The complete information on which this statement is based, including evidence tables and references, is included in the evidence synthesis available through the USPSTF Web site (http://www.preventiveservices.ahrq.gov). The recommendation is also posted on the Web site of the National Guideline Clearinghouse (http://www.guideline.gov).
Comment in
-
Taking family history seriously.Ann Intern Med. 2005 Sep 6;143(5):388-9. doi: 10.7326/0003-4819-143-5-200509060-00015. Ann Intern Med. 2005. PMID: 16144898 No abstract available.
-
Genetic risk assessment and BRCA mutation testing.Ann Intern Med. 2006 Feb 21;144(4):303-4; discussion 304. doi: 10.7326/0003-4819-144-4-200602210-00017. Ann Intern Med. 2006. PMID: 16490919 No abstract available.
-
Review: only women with specific family histories should be referred for counseling or evaluation for BRCA breast and ovarian cancer susceptibility testing.ACP J Club. 2006 Mar-Apr;144(2):37. ACP J Club. 2006. PMID: 16539352 No abstract available.
Similar articles
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2014 Feb 18;160(4):271-81. doi: 10.7326/M13-2747. Ann Intern Med. 2014. PMID: 24366376
-
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. JAMA. 2019. PMID: 31429903
-
Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations.Ann Intern Med. 2005 Sep 6;143(5):I47. doi: 10.7326/0003-4819-143-5-200509060-00005. Ann Intern Med. 2005. PMID: 16144889 No abstract available.
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.Ann Intern Med. 2005 Sep 6;143(5):362-79. doi: 10.7326/0003-4819-143-5-200509060-00012. Ann Intern Med. 2005. PMID: 16144895 Review.
-
Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.Ann Intern Med. 2014 Feb 18;160(4):255-66. doi: 10.7326/M13-1684. Ann Intern Med. 2014. PMID: 24366442 Review.
Cited by
-
Validation of a guidelines-based digital tool to assess the need for germline cancer genetic testing.Hered Cancer Clin Pract. 2024 Nov 8;22(1):24. doi: 10.1186/s13053-024-00298-0. Hered Cancer Clin Pract. 2024. PMID: 39516903 Free PMC article.
-
The ENGAGE study: a 3-arm randomized hybrid type 1 effectiveness and implementation study of an in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic services in childhood cancer survivors.BMC Health Serv Res. 2024 Feb 28;24(1):253. doi: 10.1186/s12913-024-10586-z. BMC Health Serv Res. 2024. PMID: 38414045 Free PMC article. Clinical Trial.
-
A cost-utility analysis of BRCA1 and BRCA2 testing in high-risk breast cancer patients and family members in Thailand: a cost-effective policy in resource-limited settings.Front Public Health. 2023 Dec 14;11:1257668. doi: 10.3389/fpubh.2023.1257668. eCollection 2023. Front Public Health. 2023. PMID: 38162618 Free PMC article.
-
Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps.JCO Precis Oncol. 2023 Sep;7:e2300290. doi: 10.1200/PO.23.00290. JCO Precis Oncol. 2023. PMID: 38061009 Free PMC article. Review.
-
A mainstreaming oncogenomics model: improving the identification of Lynch syndrome.Front Oncol. 2023 May 26;13:1140135. doi: 10.3389/fonc.2023.1140135. eCollection 2023. Front Oncol. 2023. PMID: 37305562 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
